Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

TVTX Relative to the S&P 500

TVTX Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Travere Therapeutics, Inc. (NASD:TVTX) seasonal charts above shows that a Buy Date of June 20 and a Sell Date of September 12 has resulted in a geometric average return of 17.71% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 14 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 36.9% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) – rare kidney disorders that often cause end-stage kidney disease.

To download TVTX seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: TVTX